Get the Stockscreener App
1.73
11.73%
-0.23
Pacific Biosciences Of California Inc stock is traded at $1.73, with a volume of 10.41M.
It is down -11.73% in the last 24 hours and up +29.10% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.96
Open:
$1.96
24h Volume:
10.41M
Relative Volume:
0.56
Market Cap:
$537.74M
Revenue:
$160.03M
Net Income/Loss:
$-128.58M
P/E Ratio:
-4.0534
EPS:
-0.4268
Net Cash Flow:
$-121.21M
1W Performance:
-25.75%
1M Performance:
+29.10%
6M Performance:
+6.13%
1Y Performance:
-1.70%
1-Day Range:
$1.70
$1.96
1-Week Range:
$1.70
$2.2859
52-Week Range:
$1.07
$3.435
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.73 | 537.74M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Resumed | UBS | Neutral |
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California, Inc. (PACB) Latest Stock News & HeadlinesYahoo Finance - Yahoo! Finance Canada
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors - Yahoo! Finance Canada
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors - Zacks Investment Research
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewswire
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics - TradingView
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics - Zacks Investment Research
PACB5949325 Bond Profile: Coupon and Redemption - TradingView
Weekly Recap: PACB Q2 results, narrowed guidance and TychoBio RNA AI - TradingView
Form 144 Pacific Biosciences of California For: 11 October By Investing.com - Investing.com South Africa
Pacific Biosciences CFO reports $2.05m stock sale - Investing.com
Form 4 Pacific Biosciences of California For: 10 October By Investing.com - Investing.com Nigeria
PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage Neutral - Yahoo Finance
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - Yahoo Finance UK
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - Zacks Investment Research
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - Yahoo Finance
Pacific Biosciences of California Insider Sold Shares Worth $2,056,921, According to a Recent SEC Filing - www.marketscreener.com
PACB Slides As UBS Starts Coverage With Neutral Target - StocksToTrade
Harnessing the Kivvi tool to resolve the genetics of FSHD with HiFi sequencing - PacBio
Pacific Biosciences of California (PACB) Institutional Ownership 2026 - MarketBeat
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25 - Moomoo
Pacific Biosciences of California (NasdaqGS:PACB) Stock Forecast & Analyst Predictions - Simply Wall Street
500,000 option-exercise shares are part of an officer's planned sale at Pacific Biosciences (PACB). - Stock Titan
PACB Stock Slides As UBS Starts Coverage With Neutral Call - StocksToTrade
PacBio Slides as Recent Rally Cools and Investors Reassess Turnaround Risks - Quiver Quantitative
PacBio Sinks 8% as TychoBio Endorses Its “Highest Quality Biological Data” – the Real Story Is More Complicated - Yahoo Finance
PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally - Yahoo Finance
PacBio (PACB) Partners with TychoBio to Advance RNA Therapy Deve - GuruFocus
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks - Benzinga
Pacific Biosciences of California, TychoBio Collaborate to Generate Full-Length RNA Data for AI Model Training - Yahoo Finance
Pacific Biosciences of California, Inc. (PACB) stock price, news, quote and history - Yahoo Finance Singapore
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics - marketscreener.com
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics - GlobeNewswire
Why PacBio (PACB) Stock Is Trading Up Today - Yahoo Finance
Why PacBio (PACB) Stock Is Trading Up Today - StockStory
Why PacBio (PACB) Stock Is Trading Up Today - The Globe and Mail
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
PACB5630687 Bond Profile: Coupon and Redemption - TradingView
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts - Yahoo Finance
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts - Zacks Investment Research
Pacific Biosciences of California Company Profile & Introduction - Moomoo
PACB Stock Climbs As Traders Eye Conference Catalyst - StocksToTrade
3 Biotech Stocks Put Traders Are Targeting Today - Yahoo Finance
Powered by PacBio: Selected publications from July – September 2026 - PacBio
Pacific Biosciences: Stock Surges As New Use Case SeenBut Caution Is Warranted (PACB) - Seeking Alpha
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
Pacific Biosciences Up Over 30%, On Pace for Largest Percent Increase Since July 2024 -- Data Talk - Moomoo
Why Is PacBio (PACB) Stock Soaring Today - TradingView
PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat - timothysykes.com
PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat - StocksToTrade
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex - Yahoo Finance
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jim Gibson | Officer |
Oct 06 '26 |
Proposed Sale |
2.87 |
661,815 |
1,899,409 |
0 |
| Gibson James R II | See Remarks |
Oct 06 '26 |
Sale |
3.11 |
661,815 |
2,056,921 |
1,083,848 |
| MARK VAN OENE | Officer |
Aug 17 '26 |
Proposed Sale |
1.13 |
26,911 |
30,512 |
0 |
| Van Oene Mark | See Remarks |
Aug 17 '26 |
Sale |
1.13 |
26,911 |
30,409 |
2,705,853 |
| Gibson James R II | See Remarks |
Apr 01 '26 |
Sale |
1.37 |
88,185 |
120,813 |
1,245,663 |
| JAMES GIBSON | Officer |
Apr 01 '26 |
Proposed Sale |
1.37 |
88,185 |
120,778 |
0 |
| HENRY CHRISTIAN O | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
12,497 |
18,920 |
3,581,813 |
| Van Oene Mark | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
6,504 |
9,847 |
2,243,634 |
| MARK D. VAN OENE | Officer |
Mar 03 '26 |
Proposed Sale |
1.51 |
6,504 |
9,849 |
0 |
| Farmer Michele | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
2,979 |
4,510 |
305,948 |
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):